G2GBIO

What G2GBIO does

G2GBIO (지투지바이오 / Good to the Globe Biotech Company) is a clinical-stage Korean biotechnology firm founded in March 2017 by CEO Heeyong Lee, a 27+ year veteran of sustained-release drug delivery research from Peptron. The company is headquartered in Cheongju (Osong BioValley), South Korea, with a Seoul business development office and a GMP manufacturing facility also located in Cheongju. Listed on KOSDAQ in August 2025 at an estimated market capitalization of approximately 3.1 trillion KRW, G2GBIO is loss-making and pre-revenue, with cumulative sales of only ~200 million KRW against cumulative operating losses of ~9.2 billion KRW through Q3 2024.

The company's core technology is the proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) — a biodegradable PLGA microsphere drug delivery system that achieves drug loading above 60% for small molecules and above 50% for peptides, suppresses initial burst release, and enables sustained drug release from one week to over six months. InnoLAMP is paired with proprietary manufacturing methods including membrane emulsification and continuous solvent removal, supporting batch production of 30-60kg and a planned second GMP plant targeting ~7 million semaglutide patient-treatments per year by 2027. An extension platform, InteLAMP, applies the same microsphere technology to local-acting anticancer drug delivery within tumor tissue. The pipeline spans GB-5001 (donepezil, Alzheimer's), GB-5112 (rivastigmine), GB-6002 (ropivacaine, post-operative pain), GB-7001 (semaglutide, obesity/diabetes), GB-5021/5023 (brexpiprazole, schizophrenia), and additional assets across hepatitis B, prostate cancer, osteoarthritis, androgenetic alopecia, and veterinary applications.

G2GBIO operates a B2B enterprise model centered on technology licensing and co-development with global pharmaceutical companies, complemented by CDO/CDMO service contracts. Revenue is generated through upfront payments, development milestones, royalties on net sales, and service fees. Core partners include Samsung Bioepis (flagship licensing deal for semaglutide-based obesity treatments, March 2026), Boehringer Ingelheim (two peptide formulation contracts in 2025), Korea Pharma and Humedix (GB-5001 domestic commercialization), HanWha Pharma (GH-001 hepatitis B), and a Master Service Agreement with a global top-20 pharma company. The company retains global manufacturing rights in its licensing deals and supplies finished products to marketing partners. As of early 2026, no licensing payments or CDMO sales had been recognized despite multiple signed agreements.

Name

G2GBIO

Legal name

주식회사 지투지바이오

Website

https://g2gbio.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

G2GBIO is a clinical-stage Korean biotech (KOSDAQ-listed) that develops long-acting injectable microsphere formulations through its proprietary InnoLAMP platform, licensing the technology and co-developing pipeline assets with global pharmaceutical partners including Samsung Bioepis and Boehringer Ingelheim.

Ownership category

akta.pro rank

Product category

Long-acting injectable drug delivery

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Long-acting injectables
• Microsphere drug delivery
• Sustained-release formulations
• Biodegradable polymer platforms
• Pharmaceutical CDMO services

Headquarters

HQ city

Cheongju

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Supply Chain

Revenue model

1. Technology Licensing and Transfer: G2GBIO licenses its InnoLAMP platform technology and pipeline assets to global pharmaceutical companies in exchange for upfront payments, milestone payments, and ongoing royalties on net sales. Key deals include Samsung Bioepis (semaglutide, two assets) and ongoing negotiations with multiple global pharma companies. The company receives technology transfer fees, development milestones, and royalty payments upon commercialization.
2. CDO/CDMO Services: Contract Development Organization (CDO) and Contract Development and Manufacturing Organization (CDMO) services utilizing the InnoLAMP microsphere platform. G2GBIO provides formulation development, scale-up research, and GMP manufacturing of microsphere injectables for partner companies on a project fee basis. A Master Service Agreement with a global top-20 pharma company is in place, with project-based orders expected to generate revenue.
3. Product Sales (Future): Once pipeline products complete clinical development and receive regulatory approval, G2GBIO plans to commercialize through manufacturing and supply agreements with distribution partners. The company retains global manufacturing rights and supplies finished products to marketing partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

G2GBIO is a clinical-stage biotechnology company that develops and licenses proprietary long-acting injectable drug delivery platforms (InnoLAMP and InteLAMP) built on biodegradable polymer microsphere technology, together with a pipeline of sustained-release injectable pharmaceutical candidates spanning Alzheimer's, obesity/diabetes, post-operative pain, schizophrenia, hepatitis B, and other therapeutic areas. The company monetizes through technology licensing and co-development agreements with global pharmaceutical partners, CDO/CDMO service contracts, and — once approved — manufacturing supply to marketing partners.

Product overview

G2GBIO is a clinical-stage biotech company specializing in long-acting injectable drug delivery platforms. The company's core technology is the InnoLAMP (Innovative Long-Acting Microsphere Platform) for developing sustained-release microsphere injectables that maintain drug efficacy from one week to over six months. The second platform, InteLAMP, extends InnoLAMP for local-acting anticancer treatments. The product portfolio includes pipeline candidates spanning multiple therapeutic areas: GB-5001/GB-5001A (donepezil for Alzheimer's disease), GB-5112 (rivastigmine), GB-6002 (ropivacaine for post-operative pain), GB-7001 (semaglutide for diabetes/obesity), GB-5021/GB-5023 (brexpiprazole for schizophrenia), GB-5313 (osteoarthritis), GB-7101/GB-7103 (prostate cancer), GB-6201/GB-6203 (androgenetic alopecia), GH-001 (hepatitis B), and veterinary products GB-2001 and GB-2006. The company offers CDO/CDMO services leveraging its GMP facilities.

Differentiator

Problem solved

Functional benefit

Brands

• InnoLAMP: Proprietary Innovative Long-Acting MicroParticle platform technology for sustained-release drug delivery
• InteLAMP

Products and services

• InnoLAMP (Innovative Long-Acting Microsphere Platform)

Quantifiable outcome

• GB-5001 (donepezil): >98 days of PK activity demonstrated in clinical studies; 56-day sustained release for 1-month formulation, 112-day for 3-month formulation of brexpiprazole
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Samsung Bioepis Co. Ltd. and Epis NexLabcoreStrategic or Co-development Partner · 16 March 2026Samsung Bioepis (a subsidiary of Samsung Epis Holdings) and Epis NexLab signed a joint research and license agreement with G2GBIO to develop long-acting obesity treatments using G2GBIO's microsphere technology. Samsung Bioepis obtained exclusive development and commercialization rights for two assets including a long-acting semaglutide-based obesity drug candidate, with options for additional assets. Samsung Epis Holdings invested 20 billion KRW ($13.35M) in convertible bonds issued by G2GBIO to strengthen the strategic partnership. G2GBIO retains global manufacturing rights.
• NovaCellminorStrategic or Co-development Partner · 4 December 2025G2GBIO and NovaCell signed an MOU for joint development of next-generation biodegradable microsphere-based peptide immunotherapy. The collaboration combines NovaCell's PEPTIROID immune-modulating peptide technology with G2GBIO's InnoLAMP and InteLAMP platforms to develop sustained-release injectable formulations for chronic inflammatory and autoimmune diseases including atopic dermatitis, rheumatoid arthritis, ulcerative colitis, and psoriasis.
• European Global Pharmaceutical Company (undisclosed)minorStrategic or Co-development Partner · 21 November 2025G2GBIO signed a research collaboration agreement with a European global pharmaceutical company in September 2025 for sustained-release injectable development using InnoLAMP technology. G2GBIO provides prototype formulations for preclinical PK/PD evaluation; the partner conducts animal testing and evaluation, with an exclusive option to license the developed formulation for commercialization.
• Ministry of Trade, Industry and Energy / Korea Materials & Components Technology Evaluation InstituteminorOthers · 12 November 2025G2GBIO selected as a recipient of the Ministry of Trade, Industry and Energy's 2025 Materials and Components Technology Development Project. Awarded 2.5 billion KRW over 2.5 years for development of a 1-month sustained-release immunosuppressant injection for organ transplant patients using InnoLAMP technology.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 24 January 2025Boehringer Ingelheim (Germany) signed a formulation development contract with G2GBIO for long-acting injectable peptide formulations using the InnoLAMP platform. A second additional formulation development contract was signed in July 2025. Boehringer Ingelheim provides proprietary peptide drugs; G2GBIO develops sustained-release microsphere formulations. Both contracts are part of ongoing strategic collaboration.
• Global Top-20 Pharmaceutical Company (undisclosed)coreStrategic or Co-development Partner · 26 April 2023G2GBIO signed a Master Service Agreement (MSA) with a global pharmaceutical company ranked in the top 20 by market capitalization for microsphere sustained release technology services. G2GBIO provides CDO (contract development organization) and CDMO services from formulation development through commercial manufacturing. The partner conducted GMP facility inspections in October 2024 as part of technology transfer evaluation. Project-specific contracts and CDO/CDMO revenue expected to begin in 2024+.
• Korea Pharma and HumedixcoreStrategic or Co-development Partner · 5 October 2022G2GBIO entered a joint development agreement with Korea Pharma and Humedix for donepezil long-acting injectable (GB-5001) for Alzheimer's disease. G2GBIO applies InnoLAMP technology for formulation development and manufacturing; Korea Pharma and Humedix conduct clinical trials, regulatory filing, and domestic sales. Partners pay milestone payments and royalties upon commercialization, and retain domestic rights.
• BC World PharmaminorChannel Partner/ Reseller/ Distributor · 17 August 2022G2GBIO signed a manufacturing cooperation agreement with BC World Pharma to leverage BC World Pharma's production infrastructure for InnoLAMP-based sustained-release injectable manufacturing. BC World Pharma's Yeoju facility (optimized for export to advanced markets) produces G2GBIO products. The agreement adds production capacity to accelerate pipeline development.
• Keyfron Bio (BiotoxTech subsidiary)minorStrategic or Co-development Partner · 27 April 2022G2GBIO and Keyfron Bio (a subsidiary of BiotoxTech) entered a joint development agreement for veterinary medicines. Keyfron Bio is responsible for clinical development of GB-2006 (animal post-operative pain treatment) and GB-2001 (animal castration). G2GBIO supplies formulation and manufacturing. BiotoxTech reportedly achieved ~13x return on its 1 billion KRW investment in G2GBIO.
• HanWha PharmacoreStrategic or Co-development Partner · 26 April 2022G2GBIO and HanWha Pharma signed a joint development agreement for a 3-month sustained-release hepatitis B antiviral injection (GH-001) using entecavir. G2GBIO handles formulation development and manufacturing; HanWha Pharma conducts clinical trials, regulatory approval, and sales, with rights to overseas markets.

Scale indicators8 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Peptron: Korean sustained-release peptide delivery company specializing in long-acting injectable microsphere formulations; G2GBIO's CEO Lee Hee-yong and Head of R&D Eunyoung Seol both previously led sustained-release programs at Peptron, making it the most directly comparable peer in technology and heritage.
• Camurus: Swedish specialty pharma company developing long-acting injectable depot formulations using its proprietary FluidCrystal technology; directly comparable to G2GBIO's InnoLAMP platform in targeting the same long-acting injectable market with similar drug delivery economics.

Broad incumbents

• Evonik Industries (Health Care): Global specialty chemicals company with a major pharmaceutical CDMO business including biodegradable PLGA polymers and injectable formulation services; a competitor/partner in the microsphere CDMO space and comparable as a scaled drug-delivery manufacturing platform.
• Pacira BioSciences: US-listed specialty pharma commercializing EXPAREL, a long-acting bupivacaine injectable for post-operative pain; comparable to G2GBIO's GB-6002 (long-acting ropivacaine) and represents a successful commercial template for sustained-release injectable platforms in the pain management space.
• Luye Pharma Group: China-headquartered specialty pharma with long-acting injectable CNS portfolio (e.g., Risperdal Consta biosimilar, ER liposomal platforms); comparable in the long-acting injectable antipsychotic/schizophrenia space where G2GBIO's GB-5021/GB-5023 competes.
• Halozyme Therapeutics: US biotech commercializing the ENHANZE drug delivery platform (recombinant human hyaluronidase) for subcutaneous large-volume injectables; comparable business model of licensing proprietary delivery technology to global pharma for co-development and royalty revenue.
• Novartis - Signifor LAR franchise: Owner of Signifor LAR (pasireotide long-acting release), used as another key commercial benchmark for InnoLAMP's high peptide drug-loading claims; reference standard for long-acting peptide microsphere technology.

Others

• Johnson & Johnson (Janssen) - Risperdal Consta franchise: Owner of Risperdal Consta, the long-acting injectable risperidone microsphere product used as a key commercial benchmark for G2GBIO's InnoLAMP drug-loading and PK performance claims.
• Ashland (Pharmaceutical Specialties): Global specialty chemicals company providing pharmaceutical excipients, polymers, and drug delivery enabling technologies for sustained-release injectables; comparable as an enabling infrastructure participant in the long-acting injectable CDMO ecosystem.

Regional players

• Samyang Biopharm: Korean specialty pharma with biodegradable polymer drug delivery expertise and long-acting injectable development capabilities; comparable Korean peer in sustained-release microsphere technology and therapeutic positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@g2gbio
• LinkedInlinkedin.com/company/g2gbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about G2GBIO